Spoštovani kupci!
Zaradi prenove spletne strani in prehoda na OJS spletna prodaja trenutno ne dela. Prosim, če sporočite, kaj bi radi kupili, na prodaja@medrazgl.si. Dopišite vaše ime in priimek, naslov ter način plačila (s predračunom, ob povzetju ali z gotovino, če prezvamete gradivo v živo v prostorih uredištva v času uradnih ur).
Hvala za razumevanje!
MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Kirurgija » | Latest edition »

Percutaneous Treatment of Mitral Regurgitation with MitraClip System

 

This post is also available in: English Slovenščina (Slovenian)

Mitral regurgitation is defined as a systolic retrograde blood flow from the left ventricle to the left atrium. Moderate or severe mitral regurgitation can be found in 10% of people older than 75 years. It is treated surgically, usually by valvuloplasty. Patients treated by medical treatment alone have a poor prognosis. Percutaneous treatment is becoming the treatment of choice for patients at high surgical risk. It is indicated in patients with severe, symptomatic mitral regurgitation and patients with severe mitral regurgitation associated with left ventricular dysfunction. We can treat both, patients with degenerative and functional mitral regurgitation. It can be used in patients with all three types of mitral regurgitation as defined by Carpentier classification, with the exception of type IIIa. The goal is to reduce the size of the regurgitation orifice by clamping both mitral leaflets. The procedure is carried out through the inguinal vein using a special guiding catheter and a clip delivery system. It is guided by fluoroscopy and transesophageal echocardiography. During the procedure we have to perform a trans-septal puncture between both atria. If necessary, we can insert more than one clip. After the procedure, patients should be receiving clopidogrel (75mg per day) for one month and a life-long therapy with acetylsalicylic acid (100 mg per day). Possible complications are those associated with cardiac catheterization and trans-septal puncture. Acute renal failure is more frequent than in other interventional procedures, another possible complication is clip detachment. Initially the procedure does not reach the results of surgical treatment, but the difference decreases with time and becomes statistically insignificant at four years follow up. Oneyear survival rate is approximately 50% better than in patients on medical treatment. In 53% of patients, regurgitation decreases for two grades or more.

© 2024 Društvo Medicinski razgledi | Na vrh strani / To top ↑